InspireMD Secures $58 Million in Funding Following FDA Approval of CGuard Prime Carotid Stent
InspireMD Inc. has successfully secured approximately $58 million in combined gross proceeds through equity private placement and warrant exercises following the FDA's premarket application approval of their CGuard Prime carotid stent system. This financial boost, detailed in their Form 8-K filing, will support the commercialization of the stent system, which is designed to prevent strokes. The PIPE, totaling $40.1 million, was led by investors OrbiMed and Marshall Wace, with contributions from both new and existing investors, as well as InspireMD board members. BofA Securities facilitated the transaction, which is expected to close by August 1, 2025. The funds will be used to enhance sales, marketing, research, and overall operations as InspireMD prepares to expand its market presence in the U.S.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InspireMD Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-021675), on July 31, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。